GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells

被引:0
作者
Zi-Jian Lan
YunHui Hu
Sheng Zhang
Xian Li
Huaxin Zhou
Jixiang Ding
Carolyn M. Klinge
Brandie N. Radde
Austin J. Cooney
Jin Zhang
Zhenmin Lei
机构
[1] Alltech Inc.,Division of Life Sciences, Center for Nutrigenomics & Applied Animal Nutrition
[2] Tianjin Medical University Cancer Institute & Hospital,The 3rd Department of Breast Cancer, National Clinical Research Center of Cancer
[3] University of Louisville Health Sciences Center,Department of OB/GYN & Women’s Health
[4] University of Louisville Health Sciences Center,Birth Defects Center, Department of Molecular, Cellular and Craniofacial Biology
[5] University of Louisville Health Sciences Center,Department of Biochemistry & Molecular Genetics
[6] The University of Texas at Austin Dell Medical School,Department of Pediatrics
来源
Breast Cancer Research and Treatment | 2016年 / 158卷
关键词
GGNBP2; Breast cancer; ERα; Tumorigenesis; Tumor suppressor;
D O I
暂无
中图分类号
学科分类号
摘要
Gametogenetin-binding protein 2 (GGNBP2) is encoded in human chromosome 17q12-q23, a region known as a breast and ovarian cancer susceptibility locus. GGNBP2, also referred to ZFP403, has a single C2H2 zinc finger and a consensus LxxLL nuclear receptor-binding motif. Here, we demonstrate that GGNBP2 expression is reduced in primary human breast tumors and in breast cancer cell lines, including T47D, MCF-7, LCC9, LY2, and MDA-MB-231 compared with normal, immortalized estrogen receptor α (ERα) negative MCF-10A and MCF10F breast epithelial cells. Overexpression of GGNBP2 inhibits the proliferation of T47D and MCF-7 ERα positive breast cancer cells without affecting MCF-10A and MCF10F. Stable GGNBP2 overexpression in T47D cells inhibits 17β-estradiol (E2)-stimulated proliferation as well as migration, invasion, anchorage-independent growth in vitro, and xenograft tumor growth in mice. We further demonstrate that GGNBP2 protein physically interacts with ERα, inhibits E2-induced activation of estrogen response element-driven reporter activity, and attenuates ER target gene expression in T47D cells. In summary, our in vitro and in vivo findings suggest that GGNBP2 is a novel breast cancer tumor suppressor functioning as a nuclear receptor corepressor to inhibit ERα activity and tumorigenesis.
引用
收藏
页码:263 / 276
页数:13
相关论文
共 533 条
[1]  
Narod SA(1991)Familial breast-ovarian cancer locus on chromosome 17q12-q23 Lancet 338 82-83
[2]  
Feunteun J(1991)Accumulation of genetic alterations and progression of primary breast cancer Cancer Res 51 5794-5799
[3]  
Lynch HT(1998)Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters Cancer Res 58 1004-1012
[4]  
Watson P(2013)Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk PLoS Genet 9 e1003212-15
[5]  
Conway T(2007)Cancer risks among BRCA1 and BRCA2 mutation carriers Br J Cancer 96 11-9
[6]  
Lynch J(2007)Cancer genetics Semin Oncol Nurs 23 2-646
[7]  
Lenoir GM(2015)Germline RECQL mutations are associated with breast cancer susceptibility Nat Genet 47 643-85
[8]  
Sato T(2004)Molecular cloning and characterization of LCRG1 a novel gene localized to the tumor suppressor locus D17S800-D17S930 Cancer Lett 209 75-344
[9]  
Akiyama F(2001)Dioxin induces a novel nuclear factor, DIF-3, that is implicated in spermatogenesis FEBS Lett 508 341-566
[10]  
Sakamoto G(2005)Yeast two-hybrid screens imply that GGNBP1, GGNBP2 and OAZ3 are potential interaction partners of testicular germ cell-specific protein GGN1 FEBS Lett 579 559-3208